Prediction: This Will Be Pfizer's Next Big Move
The Motley Fool
JULY 29, 2024
When it recently bought Seagen, a cancer biotech with advanced therapeutic technology, it was willing to take on $31 billion of debt to make the purchase. billion in debt, giving it a debt-to-equity ratio of 0.7. If the bigger business makes a bid to buy it, you'll benefit that way too. It also has just over $68.7
Let's personalize your content